Clinical Trials Browser

Breast Neoplasms

HER2 Negative Breast Cancer

Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms, Sexual Dysfunctions, Psychological

Breast Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ

Breast Neoplasms

Breast Neoplasms

Advanced Breast Carcinoma

Breast Neoplasms, Male

Breast Neoplasms

Anatomic Stage III Breast Cancer AJCC v8

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Locoregional Recurrence

Breast Neoplasms

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Breast Neoplasms

Endometrial Stromal Tumors

Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Breast Neoplasms

Breast Neoplasms

Breast Cancer Female

Breast Neoplasms

Breast Neoplasms

Breast Neoplasm Female

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

HER2-positive Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Breast Neoplasms

Granulosa Cell Ovarian Cancer

Breast Diseases, Breast Neoplasms

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Clinical Trials

CAMERAN

SELECT

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Study of 18F-FFNP Breast PET/MRI

POWER II

LoTam

GIM10-CONSENT

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

ETHAN - ET for Male BC

DEBRA

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

PHACS

OXYTAM

MIRHO

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

RaPhLRR

ADEPT

MNEMOSYNE

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

MECCA

BFR-ESS

PATINA

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

POETIC-A

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

ATRA

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

PADA-1

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

POWER

AURA

AMBRE

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

SoGreat

EUROPA

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

SoFEA

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer